This company is pioneering in the development of a new class of medicines for patients with neurodegenerative disorders. They use proprietary machine learning platform to identify small molecules that target amyloid oligomers associated with various neurodegenerative diseases. They are testing our lead molecules in mouse models of diseases and testing others in our discovery pipeline.

The company's founder has dedicated over a decade to developing machine learning models to identify chemical structures that can translate into effective therapies for neurodegenerative diseases such as Alzheimer's, ALS and Parksinson's. The team is working to make sure this work turns into treatments that get into the hands of patients.  There is already a significant amount of in vitro validation data under our belt, and we are beginning target engagement in vivo animal studies.